FDA Approves Second <br />HIV Prevention Treatment.<br />The pre-exposure <br />prophylaxis (PrEP) is <br />called Descovy. It was <br />developed by Gilead Sciences.<br />As a PrEP drug, <br />Descovy is meant <br />to be taken daily.<br />PrEP drugs are highly effective when taken as indicated in the drug labeling and can prevent <br />HIV infection, Jeffrey Murray, M.D. FDA, via CNBC.<br />Combined with safe-sex practices, <br />Descovy is recommended by the <br />FDA as a component of a broad<br />strategy to prevent new HIV infections.<br />Close to 40,000 people in the <br />U.S. were diagnosed with HIV in 2017.<br />The FDA aims <br />to reduce new HIV <br />infections by 90% by 2030
